Orchard was founded in 2015—but our roots run deeper, going back to some of the first research and clinical development involving hematopoietic stem cell, or HSC, gene therapy. Our team has played a central role in the evolution of this technology from a promising idea to a potentially life-transforming reality.
Today, we carry forward our history of visionary science to imagine new possibilities for people and families affected by genetic and other severe diseases. We’re building on decades of research to apply our HSC gene therapy platform to areas of significant medical need where we believe it may have distinct therapeutic advantages.
Orchard has acquired advanced gene therapy programs, including Strimvelis® and Libmeldy™, and continues to develop transformative treatments for rare inherited diseases such as metachromatic leukodystrophy (MLD), Wiskott Aldrich syndrome (WAS), and beta thalassemia.